Search results
28 mar 2024 · Testing scale-up and sensitization efforts across health facilities, including cervical tissue sample collection, are needed to reduce the cases of cervical cancer. This study aimed to assess the genotype-specific prevalence of clinically relevant high-risk HPV among women living with HIV in Nigeria. Methods.
15 paź 2022 · Although the cost of HPV DNA testing is one of the barriers of cervical cancer screening, especially in the LMICs, the cost of the assay used in this investigation is similar to the general HPV RT-PCR assays available in the Nigerian market.
11 lip 2023 · Among the PCR-confirmed HPV types, we found 40.98% high-risk HPV types, 27.22% low-risk HPV types, and 31.15% undetermined HPV types. Among these 25 HPV types in Nigeria, only six were included in the current nine-valent HPV vaccine.
Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer and there is growing evidence of HPV being a relevant factor in other anogenital cancers (anus, vulva, vagina and penis) and head and neck cancers. HPV types 16 and 18 are responsible for about 70% of all cervical cancer cases worldwide.
Cervical cancer ranks as the 2nd most frequent cancer among women in Nigeria and the 2nd most frequent cancer among women between 15 and 44 years of age. About 3.5% of women in the general popu-lation are estimated to harbour cervical HPV-16/18 infection at a given time, and 66.9% of invasive cervical cancers are attributed to HPVs 16 or 18.
6 lip 2023 · Conclusion: hrHPV prevalence is high in women in Nigeria and common among those HIV+ve. Rapid screening for hrHPV genotypes is recommended, and multivalent HPV vaccines should be considered...
14 cze 2021 · Despite the high burden of cervical cancer morbidity and mortality in Nigeria, there is no robust nationwide prevalence data on the HPV genotypes in Nigerian women. Thus, this study aims to determine the pooled prevalence and risk factors of genital HPV infection in Nigeria through systemic review.
